Companion Animal Vaccines Market - By Vaccine Type (Live Attenuated, Inactivated, Recombinant), By Animal Type (Canine, Feline, Equine, Avian), By Route of Administration (Injection Vaccines, Oral Vaccines, Spray Vaccines) By Distribution Channel & Forecast, 2023-2032

Companion Animal Vaccines Market - By Vaccine Type (Live Attenuated, Inactivated, Recombinant), By Animal Type (Canine, Feline, Equine, Avian), By Route of Administration (Injection Vaccines, Oral Vaccines, Spray Vaccines) By Distribution Channel & Forecast, 2023-2032

Companion Animal Vaccines Market Size

Companion Animal Vaccines Market size accounted for over USD 3 billion in 2022 and is estimated to grow at 6.6% CAGR between 2023 and 2032. High disposable income and rising prevalence of zoonotic diseases has augmented the global market growth.

To get key market trends

  Download Free Sample

Pets are largely adopted in developed countries such as Germany and U.S. majorly by elderly people for companionship. For instance, in 2022, according to the American Pet Products Association (APPA), 70% of U.S. households owns a pet. Also there has been a change in drift from pet owners to pet parents that displays pets are considered as a part of the family nowadays. Thus, increasing adoption of pets accelerates demand for companion animal vaccines market growth.
 

What are the growth opportunities in this market?

 Download Free Sample

Companion animal vaccines are biological formulations developed to protect animals from bacterial, viral, and fungal infections caused by pathogens. Companion animal vaccines are considered an effective medium to prevent diseases, and aids in limiting the disease burden in pet animals. These vaccines play an anchoring role in improving the health and welfare of animals, promoting pet health, and restrict pathogenic animal to human transmission.

Covid-19 Impact

The COVID-19 pandemic positively impacted the companion animal vaccines market owing to surge in pet adoption rates and pet ownership statistics. The COVID-19 pandemic represented an unparalleled public health crisis that has caused unprecedented & enormous disruptions to the global economy affecting multiple industrial sectors. The coronavirus transmits can from animal to animal with contact or aerosol transmission, thereby infecting other animals. Numerous incidents have been reported regarding COVID-19 infection in pet animals. For instance, as per the American Veterinary Medical Association, February 2021, 115 cats, 81 dogs were among the reported coronavirus infected cases globally. Also, in late 2020, according to World Animal Health Information System, numerous dogs and cats were infected with COVID-19 in countries such as Germany, France, Argentina, Japan among others. Hence, the above developments have promised significant spending on animal health that is further expected to upsurge the companion animal vaccines business.

Companion Animal Vaccines Market Trends

The growing incidence of zoonotic diseases across the globe is expected to drive the market expansion across the forecast timeframe. Zoonotic diseases possess substantial threat to humans as they are transferred from animals to humans. These diseases are spread through direct contact with the infected animal. The effects of zoonotic disease differ from mild symptoms to lethal circumstances leading to death. There has been an increase in incidence of zoonotic diseases such as SARS, zoonotic influenza, and rabies. These diseases are highly contagious and fatal if left untreated and can harm animals as well the humans that come in contact with these infected animals. Thus, growing incidence of zoonotic diseases across the globe along with growing need for accurate disease diagnosis and prevention will drive the demand for companion animal vaccine market growth.

Lack of well-developed infrastructure and stringent regulatory scenario for vaccine development may impede the market growth

Lack of well-developed infrastructure & resources for vaccine development and limited expenditure on pet healthcare in emerging countries may hinder the market growth. For instance, the OECD Development Co-operation Report 2020 highlighted the lack of clinical infrastructure, specific manufacturing processes, and more importantly, the financial resources in the developing world. Moreover, the Animal and Plant Health Inspection Service’s (APHIS) Center for Veterinary Biologics (CVB) regulates veterinary biologics products including animal vaccines. This regulation ensures the purity, safety, potency, and effectiveness of veterinary biologics for its use in the treatment and prevention of animal diseases.

Similarly, the European Medicines Agency (EMA) monitors the development and commercialization process of companion animal vaccines as per the technical requirements mentioned in Annex 1, Title II, to Directive 2001/82/EC, as amended by Directive 2009/9/EC, and the European Pharmacopoeia (Ph. Eur.). All commercially available animal vaccines undergo a stringent regulatory approval process and are required to meet exhaustive technical requirements. Thus, rigid regulatory framework and lack of technological & financial resources for vaccine development may impede the companion animal vaccines industry growth.

Companion Animal Vaccines Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

By vaccine type, the companion animal vaccines market is classified into live attenuated, inactivated, recombinant and others. The live attenuated segment accounted over 45% of the market share in 2022 and is projected to witness robust growth over the analysis timeframe. This majority market share is primarily owing to high clinical efficacy as compared to other vaccines type. Majority of the commercially available veterinary vaccines are live attenuated vaccines. These vaccines can induce humoral as well as cell-mediated immune responses, thereby offering long-term effectivity. Also, these vaccines are also known to induce higher immunogenicity and often, a single vaccine dose is sufficient to provide long-term protection. Live attenuated vaccines are highly preferred in emerging economies owing to high cost-effectivity as compared to other vaccines. Thus, numerous benefits associated with live attenuated are propelling the market growth positively.

Learn more about the key segments shaping this market

 Download Free Sample

By animal type, the companion animal vaccines market is divided into canine, feline, equine and avian. Canine segment accounted for over 55% market proportion in 2022 and is expected to dominate the market throughout the forecast period. The increasing segmental growth is attributed to rising adoption of dogs across the globe. Also, countries in Europe such as U.K, Poland, France are noted to have some of the highest population of pet dogs and that will attract more pet owners to opt for various core and non-core vaccines. Thus, the countries with high population of dogs as compared to other companion animals is expected to create a considerable growth opportunity for the market.

Based on route of administration, the market is segmented as injection vaccines, oral vaccines and spray vaccines. The injection segment held a significant market share in 2022 and was valued at more than USD 1.5 billion. Subcutaneous or intramuscular is the dominant route of vaccine administration in companion animals and is prioritized for diseases requiring systemic immunity. This approach optimizes the vaccine immunogenicity and reduces potential adverse reactions at the injection site. Several clinical studies have showcased the immunological benefit of injectable vaccines with minimal local side effects. Similarly, multiple studies have reported that vaccines administered through injections offer better efficiency and high humoral & cellular immune responses with a comparatively long duration of effect. Hence, high efficiency along with low side effects offered by injection vaccines promotes its preference among veterinarians, thereby accelerating the industry growth in the coming years.

Companion animal vaccines market by distribution channel is classified as veterinary hospital pharmacies, retail pharmacy, online stores. The veterinary hospital pharmacies segment held a significant market share in 2022 and is estimated to grow at 6.9% from 2022 to 2032. Companion animal vaccines are an important component of preventive healthcare for pets and are typically administered by licensed veterinarians in veterinary hospitals and clinics. Many veterinary hospitals also operate pharmacies, where pet owners can purchase prescribed medications and other products related to their pet's health. Increasing trend of companion animal vaccine manufacturers and distributors partnering with veterinary hospitals and clinics to improve the distribution of vaccines to pet owners via hospital pharmacies is expected to boost the segmental statistics.

Looking for region specific data?

 Download Free Sample

North America companion animal vaccines market accounted for significant revenue in 2022 and is anticipated to grow at 6.8% during the forecast timeframe. This dominant market share is attributed to several factors such as growing adoption of pets, increasing awareness for companion animal vaccination, and a rise in the incidence of zoonotic diseases across the country. According to the American Pet Products Association's 2021-2022 National Pet Owners Survey, there were more than 69 million pet dogs and 45 million pet cats in the U.S. households. The growing pet adoption and increasing pet healthcare expenditure are set to increase the demand for companion animal vaccines, further facilitating the regional industry growth.

Companion Animal Vaccines Market Share

Major market players operating in the companion animal vaccines industry include

• Elanco Animal Health Incorporated
• Merck & Co., Inc
• Boehringer Ingelheim International GmbH
• Zoetis Inc.

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.

Companion Animal Vaccines Industry News

• In June 2021, Zoetis announced a collaboration with Canine Companions for Independence (CCI) to provide vaccines and other healthcare products to service dogs. This strategic engagement helped the company in strengthening its product offerings with respect to canine vaccines among other health products & services. 
• In April 2021, Boehringer Ingelheim announced the launch of Feligen RCPCh, a new vaccine for cats that protects against several infectious diseases, including feline herpesvirus and calicivirus. This product launch helped the firm to bolster its position in the feline vaccine offerings and offered a competitive advantage.

The companion animal vaccines market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Vaccine Type

• Live Attenuated
• Inactivated
• Recombinant
• Others

By Animal Type

• Canine
• Feline
• Equine
• Avian

By Route of Administration

• Injection Vaccines
• Oral Vaccines
• Spray Vaccines

By Distribution Channel

• Veterinary Hospital Pharmacies
• Retail Pharmacy
• Online Stores

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Sweden
  • The Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Malaysia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Columbia
  • Chile
  • Peru
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Iran
  • Rest of MEA